Immune to Cancer: The CRI Blog
-
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
-
Donald (Dee) Rowe’s Immunotherapy Story
Melanoma | Diagnosed 2005 Every day is a bonus. Donald (Dee)’s Story Donald (Dee) Rowe loves his job… -
Donald Foley’s Immunotherapy Story
Sarcoma | Diagnosed Age 13 Every day I would feel my shoulder, and I could notice a difference…. -
Diane Altenburg’s Immunotherapy Story
Breast Cancer I thought, ‘What else can I do to help my daughters, my nieces?’ Diane’s Story… -
Michelle Boyer’s Immunotherapy Story
Melanoma | Diagnosed 2010 I would rather laugh in the face of death (and cancer) than be sad… -
Michael R’s Immunotherapy Story
Lymphoma | Diagnosed 2008 Some of the things that we’ve done over the last four years, I think,… -
Marika H’s Immunotherapy Story
Kidney Cancer | Diagnosed Age 50 I came to the realization that you only have two choices: you… -
Tom Marsilje’s Immunotherapy Story
Colorectal Cancer | Diagnosed June 4, 2012 In my 20 years of experience, I have never seen before… -
T.J. Sharpe’s Immunotherapy Story
Melanoma | Diagnosed 2012 When I was in the hospital, I made a vow that when I was…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.